drugset / Trial / NCT04877613
GFRα4 CAR T Cells in MTC Patients
Non-randomizedSequentialOpen-labelHealth-services research
Summary
This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells expressing a single-chain scFv targeting GFRα4 with tandem TCR/CD3ζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART-GFRa4 cells") in patients with incurable medullary thyroid cancer (MTC).
Timeline
- Start
- 2021-08-19
- Primary completion
- 2039-06-01
- Completion
- 2039-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CART-GFRa4 cells | Cell therapy | 2e+07 cells | Intravenous |
| Subject | CART-GFRa4 cells | Cell therapy | 5e+07 cells | Intravenous |
| Subject | CART-GFRa4 cells | Cell therapy | 1e+08 cells | Intravenous |
| Subject | CART-GFRa4 cells | Cell therapy | 3e+08 cells | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |